2015年11月11日 · Alirocumab is a PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).

2024年2月25日 · Three pharmaceutical products in the United States reduce PCSK9 activity: alirocumab, evolocumab, and inclisiran. Alirocumab and evolocumab are fully humanized monoclonal antibodies injected subcutaneously at intervals every 2 to 4 weeks, effectively lowering total and LDL-C.

Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors , and it was the first such agent ...

Two PCSK9 inhibitors are currently approved for use: alirocumab and evolocumab. Both are fully human monoclonal antibodies that bind free PCSK9. Herein we discuss the mechanism of action, efficacy, and safety of PCSK9 inhibitors. clinical problem.

PCSK9 is a proprotein convertase which is involved in the degradation of low-density lipoprotein (LDL) receptors in the liver. Mutations in the PCSK9 gene cause familial hypercholesterolaemia in a subset of patients by reducing the number of LDL receptors on the surface of hepatocytes.

Alirocumab was the first agent in the new class of PCSK9 inhibitors to be approved for clinical use. It is indicated as an adjunct to diet and maximally tolerated statin therapy in adults with HeFH or clinical ASCVD who require additional LDL-C lowering.

2018年2月19日 · Alirocumab is a human monoclonal antibody to PCSK9 (proprotein convertase subtilisin/kexin type 9), a circulating protein that modulates the activity of the LDL cholesterol receptor in the liver. The monoclonal antibody lowers serum LDL cholesterol and is used to treat severe hypercholesterolemia.

On July 24, 2015, the US Food and Drug Administration (FDA) approved alirocumab (Praluent; Sanofi), the first proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor. 18 This novel injectable monoclonal antibody therapy is indicated for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or those with clinical ather...

The recommended starting dose of PRALUENT is 75 mg once every 2 weeks administered subcutaneously, since the majority of patients achieve sufficient LDL-C reduction with this dosage. An...

Alirocumab is a monoclonal antibody used in the treatment of hypercholesterolemia and reducing the risk of cardiovascular events in patients with established cardiovascular disease.